Levodopa is the gold-standard for treatment in Parkinson`s disease, but patients often need to administer up to 6-8 doses daily due to its short half-life and wearing-off. Since frequent dosing is not possible at nighttime, around 60% of patients suffer from disabling nocturnal and early morning muscle stiffness known as early morning akinesia. Furthermore, patients may experience a delayed onset of action with the first morning dose of Levodopa, which increases and extends their morning disability. There is currently no efficient therapy available for early morning akinesia.
We are developing CP-012 in collaboration with BDD Pharma as a novel formulation of levodopa and carbidopa to be taken ad bedtime in addition to normal medication and prevent the onset of nocturnal symptoms and early morning akinesia. Contera Pharma has full ownership and holds global rights to the program.
Contera Pharma A/S
Agern Allé 24
Thomas Sager, CEO
Bukwang Pharmaceutical Co., Ltd. was established on October 17th, 1960 and has since continued to produce excellent medications with the aim of improving global health for the last 55 years.